MedPath

CTA-MCI: Cognitive Control Training in Patients With Amnestic Mild Cognitive Impairment(CTA-MCI)

Not Applicable
Conditions
Amnestic Mild Cognitive Impairment
Interventions
Behavioral: internet-based adaptive cognitive control training program
Behavioral: placebo program
Registration Number
NCT03133052
Lead Sponsor
First Affiliated Hospital of Zhejiang University
Brief Summary

This study evaluates the efficacy and mechanism of internet-based cognitive control training on episodic memory function in patients with amnestic Mild Cognitive Impairment(aMCI). Half of participants will receive adaptive internet-based cognitive control training program, while the other half will receive a fixed, primary difficulty level task.

Detailed Description

Background:

Alzheimer's disease (AD) is a common dementia in elderly populations, and amnestic mild cognitive impairment (aMCI) refers to a transitional stage between normal aging and early dementia. Patients with aMCI are at higher risks of evolving toward AD. Although it has been widely recognized that early intervention of aMCI holds the potential to delay or even reverse the cognitive impairment, no treatment is available yet. Episodic memory dysfunction is the characteristic impairment in aMCI, cognitive control training significantly improved executive function in patients with aMCI . Whether and how cognitive control training improves episodic memory function in patients with aMCI remains largely unknown.

Objectives:

The primary objective of this double-blinded, randomized RCT is to assess whether internet-based cognitive control training in patients with amnestic Mild Cognitive Impairment improves their episodic memory function. The second objective is to evaluate the effect of cognitive control training on neural plasticity, including brain activation and white matter integrity, which are assessed by functional and structural MRI.

Patients and Methods:

The proposed study is a single-center, double-blinded, randomized controlled trial that will include 70 patients diagnosed with aMCI from the neurology clinics at The First Affiliated Hospital, Zhejiang University. The patients will be randomized to either a training or a control group. The intervention is internet-based cognitive control training performed for 30 minutes over 60 sessions. Neuropsychological assessment and functional magnetic resonance imaging (MRI) will be performed before and 12 weeks after training.

Relevance:

Currently there is no known treatment available for aMCI. The proposed study is to determine the efficacy of cognitive control training on episodic memory function in patients with aMCI. Secondly, using functional and structural MRI, this study is to reveal the potential mechanism underlying cognitive control training.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Literate Chinese, aged 50 years and older
  • Complaint about memory loss and confirmed by an informant
  • Cognitive impairment in memory domain, adjusted for age and education
  • Normal or near-normal performance on general cognitive function and no or minimum impairment of daily life activities
  • Clinical dementia rating (CDR) =0.5, Mini-Mental State Examination (MMSE) score ≥ 20 (primary school) or ≥ 24 (junior school or above)
  • Failure to meet the criteria for dementia
Exclusion Criteria
  • history of clinically significant stroke
  • neurological diseases that may lead to neurological distortion, including schizophrenia, severe anxiety or depression, frontotemporal dementia,Huntington disease, brain tumor, parking disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, brain trauma, normal pressure hydrocephalus
  • systemic diseases that may lead to neurological distortion, including hypothyroidism, folic acid deficiency, vitamin B12 deficiency, severe anemia, specific infection such as HIV and syphilis
  • clinically significant gastrointestinal, renal, hepatic, respiratory, endocrine, or cardiovascular system disease;
  • cancer, alcoholism, drug addiction;
  • severe aphasia, physical disabilities, or any other factor that may preclude completion of neuropsychological testing;
  • use of medications that may affect cognitive functioning, including tranquilizers, anti-anxiolytics, hypnotics, nootropics, and cholinomimetic agents;
  • inability to undergo a brain MRI.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
training groupinternet-based adaptive cognitive control training programIntervention: Internet-based adaptive cognitive control training program. 5 x 30 minutes per week, for 12 weeks.
control groupplacebo programIntervention: placebo program: a fixed, primary difficulty level task. 5 x 30 minutes per week, for 12 weeks.
Primary Outcome Measures
NameTimeMethod
Montreal Cognitive Assessment (MoCA)12 weeks

The study uses MoCA to assess changes in the global cognitive function after an intervention of cognitive control training

Auditory Verbal Learning Test (AVLT)12 weeks

The study uses AVLT to assess changes in the episodic memory function after an intervention of cognitive control training

Secondary Outcome Measures
NameTimeMethod
White matter Integrity12 weeks

The study uses Diffusion tensor imaging and tracking (DTI) to measure changes of the Integrity of white matter after an intervention of cognitive control training

Brain response change12 weeks

The study uses task functional MRI (fMRI) to measure the brain response changes during the task after an intervention of cognitive control training

Functional connectivity across regions12 weeks

The study uses resting state functional MRI(rs-fMRI) and task fMRI to measure changes of functional connectivity across regions after an intervention of cognitive control training

Gray matter volume12 weeks

The study uses voxel-based morphometry (VBM) to measure changes of gray matter volume after an intervention of cognitive training.

Trial Locations

Locations (1)

The First Affiliated Hospital, Zhejiang University

🇨🇳

Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath